Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Preventing Olanzapine-Induced Weight Gain Using Betahistine: A Study in a Rat Model with Chronic Olanzapine Treatment
Jiamei Lian, Xu‐Feng Huang, Nagesh Pai, et al.
PLoS ONE (2014) Vol. 9, Iss. 8, pp. e104160-e104160
Open Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

Antipsychotic-associated weight gain: management strategies and impact on treatment adherence
Madhubhashinee Dayabandara, Raveen Hanwella, S. S. Ratnatunga, et al.
Neuropsychiatric Disease and Treatment (2017) Vol. Volume 13, pp. 2231-2241
Open Access | Times Cited: 258
Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management
Peter Manu, Lorena Dima, Matisyahu Shulman, et al.
Acta Psychiatrica Scandinavica (2015) Vol. 132, Iss. 2, pp. 97-108
Closed Access | Times Cited: 253
Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects
Spyridon Siafis, Dimitrios Tzachanis, Myrto Samara, et al.
Current Neuropharmacology (2017) Vol. 16, Iss. 8, pp. 1210-1223
Open Access | Times Cited: 130
The effects of antipsychotic medications on microbiome and weight gain in children and adolescents
Tali Bretler, Hagar Weisberg, Omry Koren, et al.
BMC Medicine (2019) Vol. 17, Iss. 1
Open Access | Times Cited: 76
The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Mark R. Libowitz, Erika L. Nurmi
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 61
Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes
Jiezhong Chen, Xu‐Feng Huang, Renfu Shao, et al.
Frontiers in Neuroscience (2017) Vol. 11
Open Access | Times Cited: 77
Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives
Raghunath Singh, Yashika Bansal, Bikash Medhi, et al.
European Journal of Pharmacology (2018) Vol. 844, pp. 231-240
Closed Access | Times Cited: 69
The histaminergic system as a target for the prevention of obesity and metabolic syndrome
Gustavo Provensi, Patrizio Blandina, Maria Beatrice Passani
Neuropharmacology (2015) Vol. 106, pp. 3-12
Closed Access | Times Cited: 68
<p>A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future</p>
Leslie Citrome, Joseph P. McEvoy, Mark S. Todtenkopf, et al.
Neuropsychiatric Disease and Treatment (2019) Vol. Volume 15, pp. 2559-2569
Open Access | Times Cited: 58
Understanding the Effects of Antipsychotics on Appetite Control
Sayani Mukherjee, Silje Skrede, Edward Milbank, et al.
Frontiers in Nutrition (2022) Vol. 8
Open Access | Times Cited: 35
Mechanism and treatments of antipsychotic-induced weight gain
Wujie Ye, Jingyu Xing, Zekai Yu, et al.
International Journal of Obesity (2023) Vol. 47, Iss. 6, pp. 423-433
Closed Access | Times Cited: 16
Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications
Jiamei Lian, Xu‐Feng Huang, Nagesh Pai, et al.
Pharmacological Research (2016) Vol. 106, pp. 51-63
Closed Access | Times Cited: 53
Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPKα-SREBP-1 and PPARα-dependent pathways
Xuemei Liu, Jiamei Lian, Changhua Hu, et al.
Pharmacological Research (2015) Vol. 100, pp. 36-46
Closed Access | Times Cited: 42
Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats
Paolo Lazzari, Valeria Serra, S. Marcello, et al.
European Neuropsychopharmacology (2017) Vol. 27, Iss. 7, pp. 667-678
Closed Access | Times Cited: 41
Manipulating the Circadian and Sleep Cycles to Protect Against Metabolic Disease
Kazunari Nohara, Seung‐Hee Yoo, Zheng Chen
Frontiers in Endocrinology (2015) Vol. 6
Open Access | Times Cited: 38
Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: The role of histaminergic and NPY pathways
Jiamei Lian, Michael De Santis, Meng Xiao He, et al.
Pharmacological Research (2015) Vol. 95-96, pp. 20-26
Closed Access | Times Cited: 36
Betahistine decreases olanzapine-induced weight gain and somnolence in humans
Nir Barak, Yaffa Beck, Joseph H. Albeck
Journal of Psychopharmacology (2016) Vol. 30, Iss. 3, pp. 237-241
Closed Access | Times Cited: 36
Atypical Antipsychotic Drug Olanzapine Deregulates Hepatic Lipid Metabolism and Aortic Inflammation and Aggravates Atherosclerosis
Chia‐Hui Chen, Song‐Kun Shyue, Chiao‐Po Hsu, et al.
Cellular Physiology and Biochemistry (2018) Vol. 50, Iss. 4, pp. 1216-1229
Open Access | Times Cited: 35
Adipose tissue as a target for second-generation (atypical) antipsychotics: A molecular view
Vítor Ferreira, Diana Grajales, Ángela M. Valverde
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids (2019) Vol. 1865, Iss. 2, pp. 158534-158534
Open Access | Times Cited: 33
Epigenetic histone modulations of PPARγ and related pathways contribute to olanzapine-induced metabolic disorders
Yueqing Su, Xuemei Liu, Jiamei Lian, et al.
Pharmacological Research (2020) Vol. 155, pp. 104703-104703
Closed Access | Times Cited: 32
A phenotypic Caenorhabditis elegans screen identifies a selective suppressor of antipsychotic-induced hyperphagia
Anabel Pérez‐Gómez, Maria Carretero, Natalie Weber, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 32
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain
Nir Barak, Yaffa Beck, Joseph H. Albeck
Journal of Clinical Psychopharmacology (2016) Vol. 36, Iss. 3, pp. 253-256
Closed Access | Times Cited: 24
QTc prolongation in patients with schizophrenia taking antipsychotics: Prevalence and risk factors
Wei Du, Meng‐Wei Ge, Fei‐Hong Hu, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 10, pp. 971-981
Closed Access | Times Cited: 7
Early antipsychotic exposure affects serotonin and dopamine receptor binding density differently in selected brain loci of male and female juvenile rats
Jiamei Lian, Bo Pan, Chao Deng
Pharmacological Reports (2016) Vol. 68, Iss. 5, pp. 1028-1035
Closed Access | Times Cited: 21
The histamine H3 receptor inverse agonist pitolisant reduces body weight in obese mice
Magdalena Kotańska, Kamil Kuder, Katarzyna Szczepańska, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2018) Vol. 391, Iss. 8, pp. 875-881
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top